Summary
BeiGene Ltd. (ONC) reported on December 9, 2019, the presentation of clinical data for its BTK inhibitor, BRUKINSA™ (zanubrutinib), at the 61st American Society of Hematology (ASH) Annual Meeting. The data presented focused on trials involving patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), where BRUKINSA demonstrated consistent safety and high overall response rates (ORR).
Key Highlights
- 1Presentation of clinical data for BRUKINSA™ (zanubrutinib) at the 61st ASH Annual Meeting.
- 2BRUKINSA™ showed consistent safety and high overall response rates (ORR) in patients with CLL or SLL.
- 3Preliminary efficacy and good tolerability were observed for BRUKINSA™ in combination with tislelizumab in B-cell malignancies.
- 4The event date for this announcement was December 8, 2019.
- 5The press release detailing this data is filed as Exhibit 99.1.